Watching Genmab; Shares Trading Higher After Novo Nordisk Announced Results From The FRONTIER 2 Trial In People Aged 12 Years Or Older With Haemophilia A
Watching Genmab; Shares Trading Higher After Novo Nordisk Announced Results From The FRONTIER 2 Trial In People Aged 12 Years Or Older With Haemophilia A
關注Genmab；諾和諾德公佈針對12歲及以上A型血友病患者的FRONTIER 2試驗結果後，股價走高
Watching Genmab; Shares Trading Higher After Novo Nordisk Announced Results From The FRONTIER 2 Trial In People Aged 12 Years Or Older With Haemophilia A
關注Genmab；諾和諾德公佈針對12歲及以上A型血友病患者的FRONTIER 2試驗結果後，股價走高
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。